骨关节炎
医学
安慰剂
文拉法辛
沃马克
简短疼痛清单
盐酸文拉法辛
麻醉
人口
不利影响
慢性疼痛
物理疗法
内科学
抗抑郁药
环境卫生
病理
替代医学
海马体
作者
Mark Sullivan,Susan M. Bentley,Ming-Yu Fan,Greg Gardner
出处
期刊:Pain Medicine
[Oxford University Press]
日期:2009-06-01
卷期号:10 (5): 806-812
被引量:28
标识
DOI:10.1111/j.1526-4637.2009.00637.x
摘要
OBJECTIVE: Osteoarthritis pain is a significant problem for our aging population. Non-steroidal anti-inflammatory drugs and opioids are effective treatments, but have significant adverse effects, so there is a need for alternative treatments. Selective norepinephrine-serotonin reuptake inhibitor antidepressants may provide a new treatment option for osteoarthritis pain. METHODS: We performed a single-blind placebo run-in trial of 150-225 mg of venlafaxine in 18 subjects with activity-limiting osteoarthritis pain. Each subject received 2 weeks of placebo followed by 10 weeks of venlafaxine. The primary outcome was reduction in average pain intensity between 2 and 12 weeks. For subjects not completing the trial, their last observation was carried forward as an imputed outcome. RESULTS: Average pain on the Brief Pain Inventory (BPI) was 4.7 at baseline, 4.4 after the 2-week placebo run-in, and 3.3 at 12 weeks (25% decrease, P = 0.03). Nine subjects (50%) reported at least 30% pain reduction between weeks 2 and 12. The Western Ontario and McMasters University Osteoarthritis Index (WOMAC) pain score at baseline was 2.0, 1.8 after 2 weeks, and 1.7 after 12 weeks. This represented a 6% decrease in pain between weeks 2 and 12 (P = 0.42), with two subjects (11%) reported at least 30% pain relief between weeks 2 and 12 on the WOMAC. Effects on self-reported physical and role function and depression were marginal or non-significant, and observed physical function did not improve. CONCLUSION: Venlafaxine significantly reduced pain intensity on the BPI and marginally improved self-reported function. Venlafaxine should be investigated further in a larger randomized trial for the treatment of osteoarthritis pain.
科研通智能强力驱动
Strongly Powered by AbleSci AI